Webinar Description:
The Crystalomics® Department at Ajinomoto Althea CMO uses crystallized biotherapeutics to develop high concentration, low viscosity injectable drug formulations exceeding 200 mg/mL. The first step in our technology is to discover and develop crystallization conditions as rapidly as possible in order to meet short development timelines.

Crystallization of proteins, especially monoclonal antibodies (mAbs), is very challenging and typically employs extensive trial-and-error. Incorporating high-throughput dynamic light scattering (HT-DLS) into our pre-crystallization screening to characterize the protein in multiple buffers, we are able to significantly reduce the extent of crystallization trials. Analysis of the mAbs by multi-angle light scattering coupled to size-exclusion chromatography (SEC-MALS) as well as HT-DLS is critical to determining optimal crystallization conditions with minimal time and effort.

Learning Objectives

• How light scattering can be used to rapidly characterize mAbs in multiple buffers before crystallization trials.
• How SEC-MALS can be used to characterize proteins before and after crystallization to check for degradation

Speakers:

Lynette Schroeter-Tedesco, B.S.
Chem/BioChem UCSD, Group Lead, Crystalomics®
Ajinomoto Althea Inc.

 

Lynette Schroeter-Tedesco has worked in the pharmaceutical and biotech industry for more than 20 years and has extensive experience in analytical development and characterization of both small molecules and bio-therapeutics. For the last four years, she has been developing high concentration crystalline drug products for subcutaneous injection.

Jonathan Alvarez
Master of Science Biomedical Sciences, Western University of Health Sciences, Research Associate III
Ajinomoto Althea Inc.

 

Jonathan has over 7 years of experience in protein crystallization. He has been at Althea for the last 3 years where he leads the initial crystallization discovery of all incoming molecules.